Nanoparticle delivery for transdermal HRT
- PMID: 22640909
- DOI: 10.1016/j.nano.2012.05.008
Nanoparticle delivery for transdermal HRT
Abstract
Nanomedicine is an emerging technology and the first nano-engineered medical products have come to light in the last decade. Transdermal drug delivery has significant advantages compared to other routes of drug administration. Nanoparticles unique physical and chemical properties enable transport of substances directly into the skin. The objective of this paper is to review different aspects of nanoparticle delivery, generally, and discuss its current use for transdermal hormone therapy. Transdermal estrogen therapy remains the most effective treatment for bothersome menopausal symptoms, particularly in those women for whom the potential adverse effects associated with "first pass" hepatic metabolism are to be avoided. Available alternatives for transdermal estrogen delivery include patches, gels, sprays and lotions. Other non-oral therapies which likewise avoid "first pass" hepatic metabolism include: subcutaneous implants and vaginal rings. Some of the transdermal products are associated with mild adverse skin effects such as redness and irritation, but more severe and bothersome consequences include blistering and tattooing. Even the mild adverse skin effects are frequently cited as reasons for discontinuation. Micellar nanoparticle estradiol emulsion (MNPEE) is a lotion-like therapy which constitutes an alternative transdermal delivery system not requiring the permeation enhancers or temporary skin digestion, both of which increase the possibility of irritation. MNPEE's advantages include low fluctuation of plasma estradiol concentrations, infrequent skin related adverse effects, and pleasant cosmetic-like moisturizing properties. The efficacy of MNPEE for management of menopausal vasomotor symptoms has been demonstrated in a randomized placebo controlled trial,(1) and the product is FDA approved for management of moderate to severe vasomotor symptoms. None of the observed adverse effects in the MNPEE group were statistically different from the placebo group.(1) Studies addressing inadvertent transference of estradiol to the male partners of menopausal women using this delivery technology have demonstrated small, but real amounts of transference, which do not exceed the normal physiological male estradiol range. MNPEE is safe and effective for treatment of vasomotor symptoms and represents the commercial validation of nanoparticle technology for transdermal delivery of estrogen therapy (ET) for postmenopausal women with vasomotor symptoms.
Copyright © 2012 Elsevier Inc. All rights reserved.
Similar articles
-
Nanoparticle delivery for transdermal HRT.Maturitas. 2012 Sep;73(1):74-80. doi: 10.1016/j.maturitas.2011.12.019. Epub 2012 Feb 10. Maturitas. 2012. PMID: 22325243 Review.
-
Estradiol in micellar nanoparticles: the efficacy and safety of a novel transdermal drug-delivery technology in the management of moderate to severe vasomotor symptoms.Menopause. 2006 Mar-Apr;13(2):222-31. doi: 10.1097/01.gme.0000174096.56652.4f. Menopause. 2006. PMID: 16645536 Clinical Trial.
-
Alternatives to oral estrogen replacement. Transdermal patches, percutaneous gels, vaginal creams and rings, implants, other methods of delivery.Obstet Gynecol Clin North Am. 1994 Jun;21(2):271-97. Obstet Gynecol Clin North Am. 1994. PMID: 7936545 Review.
-
Transdermal delivery of sex steroids for hormone replacement therapy and contraception. A review of principles and practice.J Reprod Med. 2003 Jul;48(7):525-40. J Reprod Med. 2003. PMID: 12953327 Review.
-
Comparison of continuous and sequential transdermal progestogen with sequential oral progestogen in postmenopausal women using continuous transdermal estrogen: vasomotor symptoms, bleeding patterns, and serum lipids.Int J Fertil Womens Med. 1997;42 Suppl 2:376-87. Int J Fertil Womens Med. 1997. PMID: 9397385 Clinical Trial.
Cited by
-
Recent Progress and Future Directions: The Nano-Drug Delivery System for the Treatment of Vitiligo.Int J Nanomedicine. 2020 May 8;15:3267-3279. doi: 10.2147/IJN.S245326. eCollection 2020. Int J Nanomedicine. 2020. PMID: 32440123 Free PMC article. Review.
-
Engineering poly(lactic-co-glycolic acid) (PLGA) micro- and nano-carriers for Controlled Delivery of 17β-Estradiol.Ann Biomed Eng. 2017 Jul;45(7):1697-1709. doi: 10.1007/s10439-017-1859-8. Epub 2017 Jun 20. Ann Biomed Eng. 2017. PMID: 28634732 Free PMC article. Review.
-
Preliminary study on carprofen concentration measurements after transcutaneous treatment with Vetdrop® in a microfracture joint defect model in sheep.BMC Vet Res. 2014 Dec 9;10:268. doi: 10.1186/s12917-014-0268-6. BMC Vet Res. 2014. PMID: 25488522 Free PMC article.
-
Therapeutic Efficacy of an ω-3-Fatty Acid-Containing 17-β Estradiol Nano-Delivery System against Experimental Atherosclerosis.PLoS One. 2016 Feb 3;11(2):e0147337. doi: 10.1371/journal.pone.0147337. eCollection 2016. PLoS One. 2016. PMID: 26840601 Free PMC article.
-
A concise review of carbon nanotube's toxicology.Nano Rev. 2013 Dec 3;4. doi: 10.3402/nano.v4i0.21521. Nano Rev. 2013. PMID: 24319547 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources